When corticotropin and cortisone became generally available in 1950 they were tested as therapeutic agents in a wide variety of morbid conditions without much consideration as to rationale. It was only natural that these hormones should be tried in a number of diseases of the nervous system in which the existing therapeutic agents are inadequate. It is the purpose of this article to review critically the results reported to date and to compare them to those obtained by Dr. Gilbert Glaser and the author8 at the Neurological Institute of the Presbyterian Hospital, in the hope that the benefits and limitations of these compounds may be determined.
A. DISEASES OF THE NEUROMUSCULAR APPARATUS 1. Progressive muscular dystrophy. Twenty cases of progressive muscular dystrophy have been treated (Table 1) . In nine cases of the juvenile or facioscapulohumeral type, there was no appreciable effect on the strength of the patient or the course of the disease. In contrast to the poor results in the juvenile type of dystrophy, Shy and McEachern" reported excellent results in the treatment of patients with a type of dystrophy which they characterize as "menopausal dystrophy" because of the relatively late onset of the symptoms. Good to excellent results were obtained in seven of eight patients with this type of muscular dystrophy. Continual administration of corticotropin or cortisone was necessary to maintain improvement. We have treated three cases of muscular dystrophy in females, in which the onset of symptoms was in middle life, without any significant change in the muscular status of the patients.
2. Myotonia atrophica and myotonia congenita. Fifteen cases with myotonic atrophica have been treated (Table 2) . Negative results were reported (Table 3) who have been treated with corticotropin or cortisone. In a small percentage of the cases, administration of these compounds is not accompanied by any significant change in the clinical condition of the patient. In the majority, however, there is a temporary exacerba-tion of the symptoms during the period of therapy, followed by a remission of symptoms of a slight, moderate, or great degree. The remission is rarely complete, consisting mainly of a decrease in the daily prostigmine requiremiient. These remissions are temporary, lasting only a few weeks to several months. Repeat treatment is usually followed by recurrence of the remission. Several patients have died in the course of the treatment or within a few weeks after the treatment had been completed. 
C. MULTIPLE SCLEROSIS
Thirty-three patients with multiple sclerosis were treated with corticotropin by Glaser and Merritt.8 Twelve (36 per cent) showed changes suggestive of significant general improvement. The specific symptom complexes most favorably affected were the spastic-paretic, cerebellar, or ataxic and acute visual. In most instances improvement was transient, appearing only during the course of treatment and lasting for only a week or two after the treatment had been discontinued. A small series of cases is being kept on McLean1' reported rapid improvement in visual acuity and decrease in size of scotomata in two patients. Gammon and his associates' reported that lessening of pain, decrease of edema of the optic nerve, and increase in visual acuity occurred one to ten days after the initiation of treatment. The final results in regard to vision were: Complete or almost complete return, seven; partial return, four; no useful vision, five. This series is too small to permit one to draw any conclusions, but it is our impression that the results reported are not significantly different from those obtained with no treatment or with other forms of treatment.
Although transient improvement may be noted in individual symptoms in patients with multiple sclerosis who are treated with corticotropin or cortisone, it can hardly be claimed that the -treatment of this disease with these compounds is on the whole satisfactory.
D. EPILEPSY
It was noted by Hoefer and Glaser9 that the administration of corticotropin may be accompanied by changes in the electroencephalogram. These changes were not of the nature to suggest that this compound would be of Dorfman , Apter, Smull, Bergenstal, and Richter.! In some of these cases the exact relationship of the seizures to the administration of the hormones is not clear, since it is known that convulsive seizures are not uncommon in several of the conditions (lupus erythematosus, periarteritis nodosa) which were the subject of these reports, but in other cases it seemed obvious that the convulsions were related to the administration of the hormones.'
Russell, Haserick, and Zucker,,' however, reported that there was improvement in the epileptiform seizures associated with lupus erythematosus while under ACTH treatment, although some of their cases had convulsions for the first time coincidental with the administration of the hormone.
Klein and Livingston" reported improvement in the seizure incidence and in the electroencephalograms of four of six children with epilepsy. In the three patients treated by Glaser and Merritt,' there was no change in the frequency of seizures. The electroencephalogram became more abnormal in one patient.
VARIOUS CONDITIONS
Thirty-five patients with acute anterior poliomyelitis (Table 5) were treated by Coriell, Siegel, Cook, Murphy, and Stokes.! ACTH was given to the patients in the early stage of the disease and the study was well controlled. The treatment had no effect on the course of the disease or on the incidence of paralysis. Similar results were reported by Millikan and Eaton1' in two cases. Experimental work in animals has shown that the administration of these hormones may increase the susceptibility to infection with the poliomyelitis virus.'
Two cases of Sydenham's chorea were treated with cortisone by Aronson, Douglas, and Lewis1 and one by Glaser and Merritt' without benefit. Schwarz," however, reported improvement in two patients with the severe form of the disease.
One patient with infectious mononucleosis with cerebral involvement was treated with ACTH and aureomycin by Huber, Bailey, Campbell, and Mathiesone0 with no appreciable effect on the course of the disease.
One case of cerebromtacular degeneration (Tay-Sach's disease) was treated by Gitman, Brusilow, and Greenblatt7 with ACTH. The treatment did not retard the progressive course of the disease.
An editorial in the United States Armed Forces Medical Journal'm reported that ACTH had been used with benefit in a few cases of postvaccinal encephalitis. No details as to symptoms, dosage, or effects of the therapy were given.
Two patients with Wilson's disease and three patients with Parkinsonism were treated by Glaser and Merritt' without any appreciable benefit.
DISCUSSION
Corticotropin and cortisone have been used in a variety of neurological diseases but have not proven to be of curative value in any of them. Temporary remission of symptoms occurred in many of the patients with myasthenia gravis. There was some improvement in a few cases of multiple sclerosis and in some patients with "menopausal dystrophy." The last observation has been made by only one group of investigators and has as yet not been confirmed by others.
CONCLUSIONS
Corticotropin and cortisone are of little or no value in the treatment of the majority of neurological diseases. In a few diseases there may be a slight degree of improvement. Short-term administration of these hormones in myasthenia gravis may be followed by temporary partial remissions.
